TLT.v Message Board - Msg: 32525067

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TLT.v

TLT.V 0.155

-16.2%

Nov 24 3:55 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: 3bar	1/29/2020 9:01:39 AM
	of 1867

We may have to go another month for the news we need for a dramatic price move . An idea copied from sthouse . Shawn Shirazi, Ph.D., CEO – Drug Division, Theralase stated “Based on the high safety and the efficacy results demonstrated in the Phase Ib study, the TLD-1433 Anti-Cancer Technology (“ACT”) platform has the potential to be a viable treatment solution for NMIBC, if the Company is able to duplicate the efficacy results observed in the Phase Ib clinical study (67% CR) at an interim analysis of approximately 20 to 25 patients enrolled and treated, Theralase plans to meet with the FDA to review the results, with a focus on obtaining accelerated approval of the Companies ACT-PDT. The 60 mill dilution may have been part of the act to get frosty out of his 19 mill warrants and a control of the company . All of coarse unless ! Cheers !

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next